We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intelligent Ultrasound Group Plc | LSE:MED | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.50 | 14.00 | 15.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMED
RNS Number : 2224V
Medaphor Group PLC
26 January 2017
MedaPhor Group plc
("the Group" or the "Company")
Patent Infringement Settlement and Trading update
MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound training simulators for medical professionals, provides the following update on the patent infringement settlement and on trading for the year to 31 December 2016.
Patent infringement settlement
Further to the statement made by the Company on 16 December 2016, the Group subsidiaries, MedaPhor Limited and MedaPhor North America Inc. (collectively "MedaPhor"), announce that MedaPhor and SonoSim Inc. and The Regents of the University of California have now formalized and executed their agreement on a patent license and patent infringement settlement. As a result, the lawsuit between the parties will be dismissed with prejudice.
Trading update
The Company reports that unaudited Group turnover for the year to 31 December 2016 grew by 50% to GBP3.3m (2015: GBP2.2m). Unaudited Global sales of ScanTrainer training simulators grew by 10% to GBP2.45m for the year to 31 December 2016. Following the acquisition of Inventive Medical Limited in August 2016, HeartWorks training simulators contributed approximately GBP0.85m to sales in the post-acquisition period.
The loss for the year before share based payment charges, but after the currently anticipated one-off costs of the SonoSim litigation and final settlement, is expected to be around GBP2.5m (2015: Loss, GBP1.5m).
Cash, at 31 December 2016 net of the anticipated litigation and settlement costs payable, was GBP1.4m.
The Board is encouraged by the sales growth achieved in 2016 despite the issues faced during the year. Following the resolution of the patent infringement action, the Board looks forward to achieving its growth targets for its US based business in FY 2017 and beyond.
This announcement contains inside information which, prior to its disclosure, was inside information for the purposes of the Market Abuse Regulation (Article 7 of Regulation (EU) No 596/2014)
Enquiries:
Hot Features
Premium
MedaPhor Group plc www.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Cenkos Securities Tel: +44 (0)20 7397 8900
Bobbie Hilliam (Nominated
Adviser)
Julian Morse (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or
medaphor@walbrookpr.com
Paul McManus / Anna Mob: +44 (0)7980 541 893 /
Dunphy Mob: +44 (0)7876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFQLFLDFFLBBD
(END) Dow Jones Newswires
January 26, 2017 06:30 ET (11:30 GMT)
1 Year Intelligent Ultrasound Chart |
1 Month Intelligent Ultrasound Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
